Thomas Flaten
Stock Analyst at Lake Street
(1.99)
# 3,113
Out of 5,245 analysts
46
Total ratings
34.15%
Success rate
-2.07%
Average return
Main Sectors:
Stocks Rated by Thomas Flaten
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RPID Rapid Micro Biosystems | Maintains: Buy | $8 → $7 | $2.06 | +239.81% | 2 | May 22, 2026 | |
| MDXH MDxHealth | Maintains: Buy | $9 → $5 | $0.80 | +525.00% | 2 | May 14, 2026 | |
| ASRT Assertio Holdings | Maintains: Hold | $22 → $24 | $23.44 | +0.26% | 5 | May 13, 2026 | |
| EVAX Evaxion | Maintains: Buy | $11 → $9 | $4.08 | +120.59% | 4 | Mar 9, 2026 | |
| IMDX Insight Molecular Diagnostics | Maintains: Buy | $8 → $12 | $6.09 | +97.04% | 1 | Feb 17, 2026 | |
| CSTL Castle Biosciences | Maintains: Buy | $35 → $52 | $20.15 | +158.06% | 7 | Jan 12, 2026 | |
| PTHS Pelthos Therapeutics | Initiates: Buy | $50 | $26.66 | +87.55% | 1 | Dec 3, 2025 | |
| CNTB Connect Biopharma Holdings | Initiates: Buy | $9 | $2.35 | +282.98% | 1 | Dec 1, 2025 | |
| HROW Harrow | Maintains: Buy | $42 → $70 | $33.00 | +112.12% | 1 | Sep 29, 2025 | |
| DERM Journey Medical | Maintains: Buy | $9 → $13 | $5.96 | +118.12% | 2 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $14 | $5.91 | +136.89% | 2 | Jul 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $2.18 | +267.82% | 1 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $40 | $14.93 | +167.92% | 1 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $17 → $9 | $9.60 | -6.25% | 5 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $8 | $4.12 | +94.17% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $9 | $8.47 | +6.26% | 2 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $11 | $4.69 | +134.54% | 3 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $25 | $23.95 | +4.38% | 2 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14,400 → $1,440 | $0.3186 | +451,877.40% | 2 | Nov 17, 2022 |
Rapid Micro Biosystems
May 22, 2026
Maintains: Buy
Price Target: $8 → $7
Current: $2.06
Upside: +239.81%
MDxHealth
May 14, 2026
Maintains: Buy
Price Target: $9 → $5
Current: $0.80
Upside: +525.00%
Assertio Holdings
May 13, 2026
Maintains: Hold
Price Target: $22 → $24
Current: $23.44
Upside: +0.26%
Evaxion
Mar 9, 2026
Maintains: Buy
Price Target: $11 → $9
Current: $4.08
Upside: +120.59%
Insight Molecular Diagnostics
Feb 17, 2026
Maintains: Buy
Price Target: $8 → $12
Current: $6.09
Upside: +97.04%
Castle Biosciences
Jan 12, 2026
Maintains: Buy
Price Target: $35 → $52
Current: $20.15
Upside: +158.06%
Pelthos Therapeutics
Dec 3, 2025
Initiates: Buy
Price Target: $50
Current: $26.66
Upside: +87.55%
Connect Biopharma Holdings
Dec 1, 2025
Initiates: Buy
Price Target: $9
Current: $2.35
Upside: +282.98%
Harrow
Sep 29, 2025
Maintains: Buy
Price Target: $42 → $70
Current: $33.00
Upside: +112.12%
Journey Medical
Aug 13, 2025
Maintains: Buy
Price Target: $9 → $13
Current: $5.96
Upside: +118.12%
Jul 18, 2025
Maintains: Buy
Price Target: $11 → $14
Current: $5.91
Upside: +136.89%
Jul 1, 2025
Initiates: Buy
Price Target: $8
Current: $2.18
Upside: +267.82%
May 14, 2025
Maintains: Buy
Price Target: $60 → $40
Current: $14.93
Upside: +167.92%
Mar 20, 2025
Downgrades: Hold
Price Target: $17 → $9
Current: $9.60
Upside: -6.25%
Mar 7, 2025
Maintains: Buy
Price Target: $10 → $8
Current: $4.12
Upside: +94.17%
Jan 8, 2025
Maintains: Buy
Price Target: $7 → $9
Current: $8.47
Upside: +6.26%
Mar 5, 2024
Maintains: Buy
Price Target: $19 → $11
Current: $4.69
Upside: +134.54%
Aug 9, 2023
Maintains: Buy
Price Target: $34 → $25
Current: $23.95
Upside: +4.38%
Nov 17, 2022
Maintains: Buy
Price Target: $14,400 → $1,440
Current: $0.3186
Upside: +451,877.40%